CTOs on the Move

Fore Biotherapeutics

www.fore.bio

 
As a leader in precision oncology, Fore Biotherapeutics provides patients with unaddressed cancer mutations new hope by connecting them with hyper-targeted medicines. Fore`s integrated functional genomics and machine learning capabilities, known as Foresight, are elucidating disease biology in competitively distinct and unparalleled ways that allow us to uniquely identify clinical-stage assets for people with few to no therapeutic alternatives. Fore is advancing its lead program, FORE8394, to treat both V600 and non-V600 BRAF mutations and continues to refine its clinical approach to serve more patient populations with difficult-to-treat mutations across oncogenes.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.fore.bio
  • 3675 Market Street
    Philadelphia, PA USA 19104
  • Phone: 215.989.4841

Executives

Name Title Contact Details
Sujit Basu
Senior Vice President and Head of Global Manufacturing and Technical Operations Profile

Similar Companies

Glyscend

Founded in 2014, Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.

Hoth Therapeutics

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs.

RxGen

RxGen is a Hamden, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tides Medical

Tides Medical is a privately funded medical technology firm located in Lafayette, LA, is a leader in the growing market for amniotic membrane technology. Our focus is on providing patients with safe, effective therapies, physicians with reliable produc...

Mana Therapeutics

MANA was founded in November 2018, based on the research and human proof-of-concept clinical trials conducted by Dr. Catherine Bollard and her team at Children`s National Hospital (CNH) in Washington, D.C., along with colleagues at Johns Hopkins Medical Center.